Curative effect of anti-fibrosis Chinese patent medicines combined with ursodeoxycholic acid for primary biliary cholangitis: A systematic review and meta-analysis

Curative effect of anti-fibrosis Chinese patent medicines combined with ursodeoxycholic acid for primary biliary cholangitis: A systematic review and meta-analysis

Blog Article

Objective: To delineate the curative effect and safety of anti-fibrosis Chinese patent medicines (CPMs) combined with ursodeoxycholic acid (UDCA) for primary biliary cholangitis (PBC).Methods: A literature search was conducted using PubMed, Web of Science, Embase, Cochrane Library, Wanfang database, VIP database, China Biology Medicine Database, and Chinese National Knowledge Infrastructure from their inception N-Acetyl Cysteine until August 2022.Randomized controlled trials (RCTs) of the treatment of PBC with anti-fibrotic CPMs were collected.

The eligibility of the publications was assessed using the Cochrane risk-of-bias tool.The evaluation indicators were the clinical efficacy rate, liver fibrosis, liver function, immune function, and symptom score.Meta-analysis and subgroup analysis were conducted to evaluate the effectiveness of anti-fibrosis CPMs.

Risk ratio (RR) was used to assess dichotomous variables, and continuous variables Pedal Strap with a 95% confidence interval were calculated using mean difference.Results: Twenty-two RCTs including 1,725 patients were selected.The findings demonstrated that anti-fibrotic CPMs combined with UDCA improved the efficacy rate, liver function, liver fibrosis, immunological indicators, and clinical symptoms compared with UDCA alone (all p < 0.

05).Conclusion: This study demonstrates that the combination of anti-fibrotic CPMs and UDCA can improve both clinical symptoms and outcomes.Nevertheless, more high-quality RCTs are needed to assess the effectiveness of anti-fibrosis CPMs for PBC.